Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
NCT03219671 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2018-12-26
Summary
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
Conditions
- Classic Kaposi Sarcoma
Interventions
- DRUG
-
nivolumab 240mg every 2 weeks
- DRUG
-
ipilimumab 1 mg/kg every 6 weeks
Sponsors & Collaborators
- collaborator INDUSTRY
-
Alona Zer
lead OTHER
Principal Investigators
-
Alona Zer, MD · Rabin Medical Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-01
- Primary Completion
- 2020-09-01
- Completion
- 2022-09-01
Countries
- Israel
Study Locations
More Related Trials
-
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719 ·Status: ACTIVE_NOT_RECRUITING
-
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
NCT04006262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
NCT01813253 ·Status: TERMINATED ·Phase: PHASE3
-
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
NCT03784040 ·Status: UNKNOWN ·Phase: PHASE1
-
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
NCT05859477 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
NCT00633295 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
NCT06437678 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
NCT02880020 ·Status: COMPLETED ·Phase: PHASE2
-
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT07315854 ·Status: RECRUITING ·Phase: PHASE2
-
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
NCT03641313 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
NCT04021108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada
NCT06361576 ·Status: COMPLETED
-
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
NCT04934618 ·Status: UNKNOWN ·Phase: PHASE2
-
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
NCT01863745 ·Status: COMPLETED ·Phase: PHASE2
-
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)
NCT03425201 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
NCT00675194 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
NCT05039736 ·Status: WITHDRAWN ·Phase: PHASE2
-
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
NCT06697366 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209664 ·Status: SUSPENDED ·Phase: PHASE2
-
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
NCT06759064 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
NCT06504615 ·Status: ACTIVE_NOT_RECRUITING